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Acebutolol and Diltiazem Improves Cardiac Function 
and Survival of Dogs Exposed to Hyperthermia
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Department of Anesthesiology, Nagasaki University School of Medicine
 Whole body hyperthermia against malignant neoplasms 
has a limited temperature because of the clinical critical 
thermal maximum. This study was carried out to determine 
whether acebutolol or diltiazem could raise a critical tem-
perature of dogs, Twentyfour male mongrel dogs were 
anesthetized with a large dose of morphine (2mg/kg), and 
randomly divided into 3 groups. Control (group C : n = 8) 
received only whole body hyperthermia (WBH). Group A (n 
= 8) received WBH and acebutolol , and Group D (n = 8) 
received WBH and diltiazem. The heart rate in control dogs 
increased by 53% at 43°C from base line, whereas it increased 
by only 7% and 9% in the presence of acebutolol and 
diltiazem, respectively. Similarly, both acebutolol and 
diltiazem significantly improved the myocardial oxygen 
extraction ratio and myocardial lactate extraction ratio so 
well as endocardial electrocardiogram ST segment elevation. 
Consequently, cardiac output and LVdp/dt max at 43°C were 
significantly improved by both acebutolol and diltiazem. 
Seventy-five percent and 87.5% of dogs administered 
acebutolol and diltiazem survived respectively, whereas none 
of control dogs survived at 44°C. In conclusion, acebutolol or 
diltiazem improves the myocardial oxygen demand-supply 
balance during hyperthermia. This effect would prevent 
circulatory collapse, and thus might raise CTMc above 42°C.
hyperthermia are becoming a mainstream of therapeutic 
hyperthermia. However, WBH would be still beneficial for 
therapy of multiple micrometastases. Mechanisms in-
volved in various organ injuries during WBH would include 
an impairment of enzyme systems, a dysfunction of the 
sympathetic nervous system, protein denaturation due to 
heat itself, exacerbation of dehydration due to an increase 
in vessel permeability'), and a decreased tissue perfusion 
resulting from heart failure. 
 We hypothesized that the heart failure would be caused 
by the abnormality of myocardial oxygen supply-demand 
relationship resulting from hyperdynamic ventricular 
function. Thus, this study was designed to determine if the 
suppression of ventricular hyperdynamics could be effec-
tive to maintain cardiovascular function and could im-
prove the outcome during WBH. Coronary and systemic 
hemodynamics were analyzed in the presence and absence 
of acebutolol or diltiazem.
Methods
Key words : acebutolol : diltiazem : cardiac function : 
          induced hyperthermia
Introduction
 Therapeutic whole body hyperthermia (WBH) is clini-
cally used as a therapy for cancer'). Irreversible biochemi-
cal damage occurs in malignant tumor cells exposed to a 
temperature of 42-44V). However, the clinical critical 
thermal maximum (CTMc), above which organ injuries 
occur, has been reported to be 41.8-42.5°C in humans-'14) and 
about 42C in dogs'). Because of this limitation of the 
applicable temperature in WBH, the technique of local
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 The experiments were approved under the Guidelines for 
Animal Experimentation at Nagasaki University and 
performed at Laboratory Animal Center for Biomedical 
Research, Nagasaki University school of medicine. 
Twentyfour male mongrel dogs weighing 13-20 kg (16.5 ± 
2.2 kg) and with Hb of 14 g/dl or higher (16.0 ± 1.8 g/dl ) 
were given kanamycin, 2.0 g, orally on the day before the 
experiment. Anesthesia was induced with pentobarbital, 20 
mg/kg i.v., and tracheal intubation was facilitated with 
0.15 mg/kg pancuronium. Morphine, 2 mg/kg i.v., was 
added to maintain anesthesia. The lungs were mechanically 
ventilated with a volume ventilator (R60 ; AIKA, Japan), 
and Pa02 and PaCO2 were adjusted to 100-150 torr and 
35-40 torr, respectively. The surgical procedure was carried 
out aseptically, and each animal received cefotiam 2HC1, 
0.5g, before starting experiment. A7-Fr polyethylene 
catheter was inserted via the left femoral artery into the 
abdominal aorta for pressure monitoring and blood 
sampling. The same type of catheter was inserted into the 
left femoral vein, through which an equivalent mixture of
lactated Ringer's and 5% dextran solutions was adminis-
tered to maintain diastolic pulmonary artery pressure 
within 80-100% of baseline throughout the experiment. 
A7-Fr pulmonary artery catheter (American Edwards 
Laboratories) was inserted from the internal jugular vein. 
Thoracotomy was performed in the fifth intercostal space, 
and a 20 gauge polyethylene catheter was inserted via the 
external jugular vein into the coronary sinus for blood 
sampling. Both aortic blood flow and left coronary artery 
blood flow were measured by electromagnetic flowmeters 
(MFX-2100 ; Nihon Kohden Co., Tokyo, Japan) placed at 
the aortic root and the origin of the left coronary artery, 
respectively. A catheter-tip transducer (PT-157 ; Goodman 
Co., Nagoya, Japan) was inserted into the left ventricle 
through the left atrium to measure the left ventricular 
pressure continuously, and the peak rate of increase in left 
ventricular (LV) pressure (LVdp/dt max) was calculated. 
An endocardial electrode insulated except the 1 mm at the 
tip was fixed under the left ventricular endocardium, 
which recorded ST segment changes in the endocardial 
ECG. The pulmonary artery temperature was measured at 
the tip of the pulmonary artery catheter, and the body 
temperature was measured with a temperature probe 
(TERUMO Finer CTM303 ; TERUMO, Japan) fixed under 
the liver with minilaparotomy. After the stabilization 
period, the dogs were randomly divided into 3 groups. 
Control (group C : n = 8) received only WBH. Group A (n 
= 8) received WBH and acebutolol , and Group D (n = 8) 
received WBH and diltiazem. In Group A, acebutolol was 
continuously administered starting at a dose of 1p g•kg-1• 
min-', and finally at a dose to maintain HR within 110% 
of baseline. In Group D, diltiazem was administered
starting at a dose of 0.5,u g • kg-1 • min-' and finally at a 
dose to maintain HR within 110% of baseline. The dog was 
wrapped with a double layer polyethylene sheet and was 
heated by immersion in warm water 4-8CC higher than the 
body temperature. The body temperature was increased at 
a rate of 0.5C/30 min, maintained at 43°C for 30 min, and 
increased further to 44°C. The measured parameters were 
heart rate (HR), systolic and diastolic blood pressures 
(SBP, DBP), pulmonary artery pressure (PAP), pulmo-
nary capillary wedge pressure (PCWP), ascending aortic 
blood flow = cardiac output (CO), left ventricular dp/dt 
max (LVdp/dt max), left main trunks coronary blood 
flow (LCBF), endocardial electrocardiogram ST segment 
changes (Endo. ECG ST change), arterial blood gases 
(ABG), coronary sinus blood gases (CBG), aortic blood 
serum lactate, coronary sinus blood serum lactate, aortic 
blood serum creatine phosphokinase myocardial band 
(CPK-MB), coronary sinus blood serum creatine 
phosphokinase myocardial band, aortic blood serum 
potassium, and coronary sinus blood serum potassium. 
Left main trunks coronary vessel resistance (LCVR, unit) 
was calculated as (diastolic aortic pressure-left ventricu-
lar end-diastolic pressure)/left main trunks coronary 
blood flow. Myocardial oxygen extraction ratio was 
calculated as arteriocoronary sinus oxygen content differ-
ence x 100/arterial oxygen content. Myocardial lactate 
extraction ratio was calculated as arteriocoronary sinus 
lactate content difference x 100/arterial lactate content. 
 Statistical analysis was performed by paired and non-
paired t-test, chi-square test, and Fisher's exact probabil-
ity test. A P value less than 0.05 was considered 
significant.
Table 1. Systemic Hemodynamic Parameters
                    °C 38 41 42 42.5 43 
HR (bpm) C 149±3 174±11° 202±10" 218±7" 230±11° 
                   A 153±3 160±2* 161±3* 158±3* 163±4*
                   D 148±5 161±8 165±5* 168±7* 172±11*
mABP (mmHg) C 90±9 108±9 102±8 98±7 51±5 
                  A 102±8 98±5 94±7 90±6 88±7*
                  D 105±6 110±6 108±6 109±7 110±7* 
CI (L/min/m2) C 1.9±0.3 2.5±0.3 2.7±0.4 2.7±0.3 1.2±0.2§ 
                       A 2.2±0.2 2.8±0.6 3.2±0.6 3.2±0.5 3.5±0.3*
                      D 2.5±0.3 2.7±0.5 3.5±0.3 3.6±0.4 3.7±0.4*
SVI (ml/b/m) C 17.3±2.5 15.8±3.0 14.1±3.3 12.3±2.4 7.1±1.2¶ 
                      A 14.9±1.2 18.2±2.0 21.1±2.6 21.0±2.7 22.4±2.5* 
                      D 17.5±2.0 18.2±1.9 20.3±2.0 20.7±1.9 20.2±3.2*
PCWP (mmHg) C 8.2±1.5 8.9±2.2 8.3±2.3 6.7±1.7 5.0±1.6 
                       A 5.9±0.8 6.8±1.0 6.6±1.2 6.1±0.8 5.9±0.7
                       D 7.2±1.1 6.7±_0.7 6.9±0.8 6.9±1.8 6.8±0.9
Data are mean±SEM.(n=8 for each value). C : control group A : acebutolol group D : diltiazem group 
HR : heart rate. mABP : mean atrial blood pressure. CI : cardiac index. SVI : stroke volume index. 
PCWP : pulmonary capillary wedge pressure 
* p<0.05 vs control. ¶ p<0.05 vs 38'C. § p<0.05 vs 42.5'C.
Table 2. Coronary Hemodynamic Parameters
                    `C 38 41 42 42.5 43 
LVdp/dt max C 2.41±0.25 2.85±0.35 3.38±0.41" 3.62±0.211 2.42±0.24§ 
(x103mmHg/s) A 2.15±0.14 2.35±0.30 2.55±0.22 2.65±0.25* 2.86±0.24¶ 
                       D 1.88±0.26 2.36±0.18 2.83±0.32 3.08±0.42¶ 3.22±0.22¶
LCBF(ml/s) C 63.6±7.2 73.2±8.2 90.6±9.4 97.3±9.9¶ 94.1±8.6" 
                       A 69.5±4.8 75.1±5.8 80.5±11.0 88.3±9.5 91.8±11.2¶
                       D 73.5±5.5 80.2±7.8 85.0±9.1 88.2±11.2 88.7±11.0
LCVR(dynexs/cm2) C 1.22±0.11 1.11±0.98 0.91±0.18 0.72±0.11" 0.65±0.09¶ 
dABP-LVEDP A 1.27±0.18 1.21±0.14 1.02±0.16 0.88±0.09 0.85±0.19 
   LCBF D 1.19±0.08 1.10±0.12 1.04±0.16 1.03±0.17 1.01±0.18
Values are mean ±SEM.(n=8 for each value). C, A, D : Refer to table 1. 
LVdp/dt max=left ventricular dp/dt max. LCBF=Left Coronary Artery Blood Flow. 
LCVR=Left Coronary Vessel Resistance. * p<0.05 vs control. ¶ p<0.05 vs 38'C. § p<0.05 vs 42.5°C.
Table 3. Coronary Sinus Blood Serum CPK-MB and Potassium
                    °C 38 41 42 42
.5 43 
CPK-MB C 3.8±2.0 4.4±2.8 5.5±3.1 6.8±2.4 18.0±3.6° 
                       A 2.8±1.9 3.8±1.4 4.5±2.6 5.5±2.8 5.2±3.1* 
                       D 4.1±2.7 4.8±2.6 5.0±3.0 5.0±2.9 6.2±3.0*
Potassium C 3.7±0.4 4.0±0.3 4.3±0.4 4.5±0.5 4.7±0.6 
                       A 3.9±0.5 4.0±0.3 4.0±0.3 4.1±0.3 4.3±0.4
                       D 3.7±0.2 4.1±0.2 4.2±0.3 4.2±0.4 4.4±0.5
Values are mean ±SEM.(n=8 for each value). C, A, D : Refer to table 1. 
CPK-MB=creatine phosphokinase myocaldial band 
* p<0.05 vs control. ¶ p<0.05 vs 38t. § p<0.05 vs 42.5`C.
Fig. 1. The effects of acebutolol and diltiazem on the 
survival during hyperthermia above 43'C. 
C : control group. 
A : acebutolol group. 
D : diltiazem group. 
*p<0.05 * *p<0.01 vs control.
Fig. 2. The effects of acebutolol and diltiazem on myocar-
dial oxygen extraction ratio during hyperthermia (mean±S 
EM ; n = 8 for each value). 
C, A, D : Refer to Fig. 1. 
*p<0.05 vs control. ¶ p<0.05 vs 38°C.
Fig. 3. The effects of acebutolol or diltiazem on myocardial 
lactate extraction ratio during hyperthermia (mean ±SEM ; 
n = 8 for each value). 
C, A, D : Refer to Fig. 1. 
*p<0.05 vs control. $ p<0.05 and § p<0.01 vs 38°C.
Results
 No significant difference was observed in body weight, 
or Hb among the three groups. 
 In Group C, 4 of 8 animals survived at 43.5°C, and none 
of them survived at 44°C. In Group A, all animals survived 
at 43.51C, and 6 of the animals survived at 44C. The 
survival rate was significantly higher in Group A than in 
Group C. In Group D, all of 8 animals survived at 43.5°C, 
and 7 of the animals survived at 44C. °The survival rate 
was significantly higher in Group D than in Group C (Fig. 
1). 
 The effects of acebutolol and diltiazem on systemic 
hemodynamics during WBH are shown in Table 1. In Group 
C, HR increased by 52% from 149 beats/min at 38° to 230 
beats/min at 43°C, and MAP decreased to 51±5 mmHg at 
43°C. In Groups A and D, HR and MAP were kept at the 
baseline level. CI was maintained in Group A (3.5±0.3 L/ 
min/m2) and Group D (3.7±0.4 L/min/m2), and decreased 
in Group C to 1.2±0.2 L/min/m2 at 43°C. 
 The effects of acebutolol and diltiazem on coronary 
hemodynamics during WBH are shown in Table 2. In Group 
C, LVdp/dt max increased as temperature increased up to 
42.51C, while it decreased markedly at 431C. In Groups A 
and D, LVdp/dt max continued to increase up to 43°C. In 
Group C, LCBF significantly increased at 42.5°C and 43°C 
compared with that at 38°C (p<0.05). LCVR significantly 
decreased at 42.5 and 43°C compared with that at 38°C.
Fig. 4. The effects of acebutolol or diltiazem on endo-
cardial ECG ST segment change during hyperthermia 
(mean±SEM ; n = 8 for each value). 
C, A, D : Refer to Fig. 1. 
* p<0.05 vs control. ¶ p<0.05 vs 38°C .
The value of serum CPK-MB was abnormal only in Group 
C at 43C (18 ± 3.6 U/ml, reference intervals 0-8 U/ml) 
(Table 3). The myocardial oxygen extraction ratio in-
creased in Group C by 82.2 ± 3.9 % at 431C. No changes 
were observed in Group A or Group D (Fig. 2). The 
myocardial lactate extraction ratio decreased in Group C 
to 4.0±3.6% at 42.5C and -5.0±4.1% at 431C, with 
significant differences compared with the value at 381C 
(Fig. 3). 
 ST segment in endocardial ECG continued to increase in 
Group C and became 2.5 mV or above at 43°C. ST segment 
showed no significant change in Group A or D at a tem-
perature up to 431C (Fig. 4).
Discussion 
 The present results show that either acebutolol or 
diltiazem could improve the coronary and systemic 
hemodynamics during induced hyperthermia resulting in a 
significant raise in CTMc in dogs. As compared with 381C, 
HR increased by 53% at 43°C in control dogs. In contrast 
the increase in HR was markedly inhibited by either 
acebutolol or diltiazem, i.e., 7% increase with acebutolol 
and 9% with diltiazem. As a result, CI and LVdp/dt max 
in Group C at 43°C were significantly reduced as compared 
with those in Groups A and D, indicating a marked 
reduction in the contraction force. No changes in the 
contraction force were observed in Group A or Group C. In
Group C, the myocardial oxygen extraction ratio exceeded 
80% (431C ) . The myocardial lactate extraction ratio 
became 0 at 42.5C and negative at 431C, suggesting that 
anaerobic metabolism was dominant at this tempera-
ture','). In Groups A and D, no significant difference was 
observed in the myocardial oxygen extraction ratio or the 
myocardial lactate extraction ratio as compared with the 
levels at 381C, suggesting that aerobic metabolism re-
mained dominant even during hyperthermia. ST segment in 
the endocardial electrocardiogram (Endo. ECG ST change) 
in Group C increased by 1 mV or more at 421C and by 2.5 
mV or more at 431C, indicating hypoxia at least in the 
subendocardial region. CPK-MB of the blood in the coro-
nary sinus increased significantly only in Group Cat 43°C, 
suggesting bleb formation due to hypoxia, collapse of the 
blebs that followed, and the consequent release of cardiac 
enzymes'). Since there were no significant differences in the 
serum potassium level in any group, the structure of the 
cell wall itself is might be intact. 
 The use of acebutolol or diltiazem during hyperthermia 
is considered to be advantageous in the following three 
respects. (1) They restrict the myocardial oxygen demand 
by preventing increases in the heart rate and contraction 
force of the heart and improve the demand-supply balance 
of oxygen. (2) 9 -blockers10) and non-dihydropyridine 
Ca-b lockers",",") themselves have protective effects on the 
myocardium against ischemia. (3) The ventricular filling 
time is obtained by restriction of the heart rate. Because 
of these advantages, the contraction force of the myocar-
dium is maintained during hyperthermia, and the oxygen 
supply to various organs is thus sustained. Moreover, 
there were no significant difference between the group 
administered acebutolol and the group administered 
diltiazem, although the mechanisms of action of the two 
drugs are totally different. Therefore, this increased 
tolerance to hyperthermia is undoubtedly ascribed to 
improvements in the myocardial oxygen demand-supply 
balance. 
 With these regimens, it is considered possible that CTMc 
would be raised above 42C and that WBH could be con-
ducted at a higher temperature. The anti-tumor effect of 
hyperthermia would increase by several times per 0.2°C at 
a temperature of 43°C or above"). Therefore, even slight 
increase in CTMc would have a great significance. In 
addition, widening of the difference between the effective 
temperature and CTMc would increase the safety of 
therapeutic hyperthermia. 
 Many experiments have been done regarding the 
hemodynamics during hyperthermia15), but their results are 
complicated by accompanied factors such as the anesthet-
ics, fluid infusion, and infection. In this study, to elimi-
nate the effects of anesthesia on the myocardium and the 
coronary blood flow as much as possible, we used barbitu-
rate only in the induction period') and avoided the use of 
gaseous anesthetics throughout the experiment17181 and
anesthetized the animals with a large dose of mor-
phine",',"). Moreover, to eliminate the effects of infection 
during hyperthermia (translocation and endotoxemia)22,23), 
kanamycin was administered orally 1 day before the 
experiment, a second generation cefem antibiotic was 
administered at the beginning of the experiment, and the 
experiment was carried out by an aseptic procedure. 
 In conclusion, acebutolol or diltiazem improves the 
myocardial oxygen demand-supply balance during 
hyperthermia. This effect would prevent circulatory 
collapse, and thus might raise CTMc above 42CC.
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